SASurasit Akkakrisee

Surasit Akkakrisee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Surasit Akkakrisee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial comparing longitudinal and cross-sectional probe location cutting techniques

    by Surasit Akkakrisee, Keerati Hongsakul, Suthasinee Arunwate, Ussanee Boonsrirat, Sorracha Rookkapan, Jitpreedee Sungsiri, Kittipitch Bannangkoon, Phurich Janjindamai, Panjai Choochuen

    Purpose To compare the efficacy of percutaneous ultrasound-guided renal biopsy using longitudinal and cross-sectional probe location cutting techniques, focusing on the adequacy of tissue sampling and potential complications. Methods In this single-center prospective randomized controlled trial (August 2023–January 2024), 70 patients with suspected renal parenchymal disease were randomly assigned to undergo biopsy using either a longitudinal (n = 35) or cross-sectional (n = 35) probe approach. Technical success was defined as obtaining ≥ 10 glomeruli. Outcomes included technical success, glomerular yield, and complications. Subgroup analyses were performed by cortical thickness (< 10 mm) and body mass index (BMI ≥ 30 kg/m²). Multivariate logistic regression was used to identify predictors of success. Results Technical success was achieved in 30/35 patients (85.7%) in the cross-sectional group and 22/35 (62.9%) in the longitudinal group (P = 0.056). Median glomerular yields were similar (20 vs. 18, P = 0.173). Complication rates were low and comparable between groups (1/35 vs. 2/35 required angioembolization). Subgroup analyses suggested higher success rates for the cross-sectional approach in obese patients (100% vs. 50%, P = 0.105) and in those with cortical thickness < 10 mm (80% vs. 42.9%, P = 0.094), though these were not statistically significant. In multivariate analysis, the cross-sectional technique (OR: 7.69; 95% CI: 1.69–50; P = 0.006) and greater cortical thickness (OR: 1.49 per mm; 95% CI: 1.06–2.25; P = 0.019) were independently associated with success. Conclusion The cross-sectional probe technique was independently associated with higher technical success in renal biopsy without increasing complications. Given the modest sample size and borderline significance in univariate analysis, subgroup findings should be considered exploratory, and larger multicenter trials are warranted for validation.


  • Open Access

    Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients With Inoperable Hepatocellular Carcinoma

    by Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Phurich Janjindamai, Surasit Akkakrisee, Teerha Piratvisuth, Alan Geater

    INTRODUCTION: Patients with unresectable hepatocellular carcinoma treated with conventional transarterial chemoembolization (cTACE) have heterogeneous tumor burden and liver function. Therefore, the selection of patients for repeated cTACE is challenging owing to different outcomes. This study aimed to establish a decision-making scoring system for repeated cTACE to guide further treatment. METHODS: All patients with hepatocellular carcinoma who underwent cTACE between 2008 and 2019 were included and randomly assigned into training (n = 324) and validation (n = 162) cohorts. Tumor Size, number of Masses, Albumin-bilirubin score, baseline Alpha-fetoprotein level, and Response to initial cTACE session were selected to generate a “SMAART” score in the training cohort. Patients were stratified according to the SMAART score: low risk, 0–2; medium risk, 3–4; and high risk, 5–8. Prediction error curves based on the integrated Brier score and the Harrell C-index validated the SMAART scores and compared them with the Assessment for Retreatment with Transarterial chemoembolization (ART) score. RESULTS: The low-risk group had the longest median overall survival of 39.0 months, followed by the medium-risk and high-risk groups of 21.2 months and 10.5 months, respectively, with significant differences (P < 0.001). The validation cohort had similar results. The high-risk group had 63.1% TACE refractory cases. The Harrell C-indexes were 0.562 and 0.665 and the integrated Brier scores were 0.176 and 0.154 for ART and SMAART scores, respectively. DISCUSSION: The SMAART score can aid clinicians in selecting appropriate candidates for subsequent cTACE. A SMAART score of ≥5 after the first cTACE session identified patients with poor prognosis who may not benefit from additional cTACE sessions.


  • Open Access

    Hepatic Vein Aneurysm: An Extremely Rare Case with Successful Embolization

    by Surasit Akkakrisee, Keerati Hongsakul, Tortrakoon Thongkan

    Hepatic vein aneurysm is an extremely rare case. The etiology of hepatic vein aneurysms is uncertain, and endovascular treatment of this condition has not been reported. We report the case of a 71-year-old woman with right upper abdominal pain who was diagnosed with hepatic vein aneurysm and was successfully treated with an endovascular technique.